PMI Latest News | Stock Alarm Pro

PMIPMI

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

Picard / SynCardia Featured on the Cruxx of MedTech Podcast

TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management.

globenewswire.com

SynCardia and Hydrix Enter into Development Collaboration to Advance the Emperor, SynCardia's Next Generation Total Artificial Heart

TUCSON, Ariz., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that on January 5, 2026 SynCardia entered into a development collaboration agreement (the “Agreement”) with Hydrix Services Pty Ltd (“Hydrix”), a wholly owned subsidiary of Hydrix Limited (ASX: HYD), to commence an initial development phase for SynCardia's next-generation, fully implantable Total Artificial Heart (TAH) technology, known as the Emperor. As a fully implantable TAH, Emperor would eliminate the use of an external driver and offer both greater convenience and increased freedom related to patient mobility.

globenewswire.com

Picard Medical to Begin Rollout of FDA-Cleared Accessory for its SynCardia Total Artificial Heart

TUCSON, Ariz., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world's first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that it would begin to incorporate an additional design component of an FDA-cleared accessory, CPC1 “Connector Covers”, into its SynCardia Total Artificial Heart (STAH) design that is intended to provide comfort during daily activities while reinforcing system safety and reliability.

globenewswire.com

Picard Medical Announces Up to $50 Million Senior Secured Debt Financing

TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has entered into a definitive agreement for a private placement financing of up to $50.0 million aggregate principal amount of senior secured notes due 2028 together with warrants to purchase common stock of the Company. WestPark Capital Inc. served as Sole Placement Agent.

globenewswire.com

Picard Medical Marks Public Company Milestone by Ringing the NYSE Opening Bell

Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company's transition to the public markets and continued advancement of their Total Artificial Heart technology Picard Medical, Inc. / SynCardia Systems LLC commemorate the Company's transition to the public markets and continued advancement of their Total Artificial Heart technology

globenewswire.com

Picard Celebrates Patient Living a World-Record of Over Eight Years with the SynCardia Total Artificial Heart

-Picard Medical / SynCardia Systems LLC mark historic milestone as a patient reaches 2,900 days of continuous support with the SynCardia Total Artificial Heart -- the longest timeframe in the world ever recorded-

globenewswire.com

Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany

TUCSON, Ariz., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Patrick NJ Schnegelsberg, CEO will attend and present data on the fully implantable Emperor Total Artificial Heart (TAH) at the upcoming CSI Focus D-HF (Device Therapies in Heart Failure) conference, scheduled for December 5th through 6th, 2025 in Frankfurt, Germany.

globenewswire.com

Picard Medical to Present the Next Generation Fully Implantable SynCardia Total Artificial Heart at ISMCS 2025

TUCSON, Ariz., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it will present in vitro data on the fully implantable Emperor Total Artificial Heart (TAH) at the 31st Annual Meeting of the International Society for Mechanical Circulatory Support (ISMCS 2025), held in Vienna, Austria from December 1st through 4th, 2025.

gurufocus.com

MGIC Investment: A High-Yield Opportunity in the Housing Market

MGIC Investment (MTG), a top provider of private mortgage insurance (PMI), is gaining attention as U.S. mortgage rates decline from last summer's peak. With a p

globenewswire.com

SynCardia Completes First In Vivo Implantations of Next-Generation Emperor Total Artificial Heart

Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technology Significant milestone reached in advancing a driverless total artificial heart, strengthening Picard Medicals leadership in total artificial heart technology

globenewswire.com

Picard Reports Third Quarter 2025 Financial Results

– Completes IPO, Expands Patent Portfolio, and Strengthens Board Independence – TUCSON, Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced financial results for the three and nine months ended September 30, 2025.

globenewswire.com

Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City

TUCSON, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will attend the Canaccord Genuity (CG) MedTech, Diagnostics and Digital Health & Services Forum to be held on November 20, 2025, in New York, NY.

globenewswire.com

Picard Issues Statement on Intraday Stock Price

TUCSON, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced that it is not aware of any undisclosed material change in the Company's operations or financial condition, that would account for the recent volatility in its stock price.

globenewswire.com

Picard Advances Patent Protection for Fully Implantable Artificial Heart Technology

- Patent portfolio secures innovation for the future of heart replacement - TUCSON, Ariz., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, today announced the strengthening of its intellectual property portfolio with the recent grant of U.S. Patent No.

globenewswire.com

Picard Medical Reports Second Quarter 2025 Financial Results

TUSCON, Ariz., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world's first U.S. and Canadian commercially-approved total artificial heart, announced financial results for the quarter and six months ended June 30, 2025. In early September, Picard successfully closed its initial public offering, raising gross proceeds of $19.5 million.

globenewswire.com

Picard Announces Appointment of Two New Members to its Board of Directors

Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership Appointments strengthen Picard's Board with proven expertise in capital markets and global MedTech leadership

globenewswire.com

Picard Medical, Inc. Announces Exercise of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

TUCSON, Ariz., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that the underwriters of its previously announced initial public offering of common stock, par value $0.0001 per share (the “Common Stock”) have exercised their over-allotment option in full on September 5, 2025, resulting in the issuance of an additional 637,500 shares of Common Stock at a public offering price of $4.00 per share, for gross proceeds of $2,550,000, before deducting underwriting discounts and estimated offering expenses. The shares began trading on the NYSE American, LLC (“NYSE American”) under the ticker symbol “PMI” on August 29, 2025.

globenewswire.com

Picard Medical, Inc. Announces Closing of $17 Million Initial Public Offering

TUCSON, Ariz., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), today announced that it closed its initial public offering of 4,250,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) at $4.00 per share (the “Offering”). The Company has granted the underwriters an option, within 30 days from the closing date of the Offering, to purchase up to an additional 637,500 shares of Common Stock the public offering price, less underwriting discounts, to cover over-allotment, if any. The gross proceeds from the offering were $17 million, before deducting underwriting discounts and estimated offering expenses. The shares began trading on the NYSE American, LLC (“NYSE American”) under the ticker symbol “PMI” on August 29, 2025.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance